Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines

Editas Medicine (EDIT) Reports Q3 Loss of $0.66

November 12, 2019 7:03 AM EST

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.66), versus ($0.32) reported last year.

"Our momentum in 2019 remains strong in advancing our pipeline of in vivo CRISPR and engineered cell medicines," said Cynthia Collins, Chief Executive Officer of Editas Medicine. We announced this morning an... More